VBI Vaccines (VBIV) Stock Price, News & Analysis

Company Overview

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.02 to $0.79
• 52-Week Range: N/A
• Volume: 29.90 million shs
• Average Volume: 3.66 million shs
• Market Capitalization: $1.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VBIV Stock Analysis - Frequently Asked Questions

How were VBI Vaccines' earnings last quarter?

VBI Vaccines Inc. (NASDAQ:VBIV) announced its earnings results on Monday, March, 13th. The biopharmaceutical company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.40) by $0.20. The biopharmaceutical company had revenue of $0.29 million for the quarter, compared to analyst estimates of $1.98 million. VBI Vaccines had a negative trailing twelve-month return on equity of 525.42% and a negative net margin of 881.79%.

When did VBI Vaccines' stock split?

VBI Vaccines shares reverse split on Wednesday, April 12th 2023.The 1-20 reverse split was announced on Wednesday, April 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of VBI Vaccines own?

Based on aggregate information from My MarketBeat watchlists, some other companies that VBI Vaccines investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Pfizer (PFE) and Novavax (NVAX).

Company Calendar

• Last Earnings: 3/13/2023
• Today: 9/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VBIV
• CIK: 764195
• Web: www.vbivaccines.com
• Phone: (617) 830-3031
• Fax: N/A
• Employees: 22
• Year Founded: 2001

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$92.84 million
• Net Margins: -881.79%
• Pretax Margin: -881.79%
• Return on Equity: -525.42%
• Return on Assets: -45.87%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.34
• Quick Ratio: 0.21

Sales & Book Value

• Annual Sales: $9.41 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.32 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 28,682,000
• Free Float: 25,713,000
• Market Cap: $1.87 million
• Optionable: Optionable
• Beta: 2.18